LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124)
Objective: to assess the long-term safety and efficiency of tocilizumab (TCZ) therapy in patients with early rheumatoid arthritis (RA) of moderate and high activity, who have completed the basic WA19926 study, as well as the rate of sustained drug-free remission.Subjects and methods. A long-term ope...
Main Authors: | E. L. Nasonov, M. L. Stanislav, V. I. Mazurov, T. M. Chernykh, V. N. Sorotskaya, T. S. Salnikova, R. S. Saikovsky, O. V. Reshet’ko, T. A. Popova, E. I. Shmidt, V. P. Tyurin, N. P. Shilkina, I. N. Bokarev, M. Z. Kanevskaya, S. S. Yakushin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2018-07-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2560 |
Similar Items
-
Optimization of systemic juvenile arthritis treatment regimens with correction of tocilizumab intravenous administration according to data of observational retrospective study
by: M. I. Kaleda, et al.
Published: (2019-05-01) -
Evaluation of the efficiency and safety of tocilizumab therapy in patients with systemic-onset juvenile idiopathic arthritis: results of a retrospective follow-up
by: M. M. Kostik, et al.
Published: (2018-01-01) -
EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY
by: Rita Aleksandrovna Osipyants, et al.
Published: (2013-12-01) -
Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study
by: Akira Onishi, et al.
Published: (2025-03-01) -
Experience with tocilizumab in patients with rheumatoid arthritis (according to the data of the LORNET multicenter trial)
by: E Yu Panasyuk, et al.
Published: (2013-04-01)